Hints and tips:
...Boehringer Ingelheim is building a new manufacturing plant but, says Dias of the EMA, “you don’t build a new site overnight”....
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...Genzyme was Sanofi’s last big deal until an €18bn asset swap with Boehringer Ingelheim in December and the group’s new chief executive, Olivier Brandicourt, has indicated there will be more ahead....
...Possible buyers include Zoetis and pharma groups that still have animal health divisions: Lilly, Bayer and possibly Boehringer Ingelheim, which is privately held....
...It is also a setback to rival companies that had been eyeing the purchase of assets set to be spun off as part of the combination, including Bayer, Boehringer Ingelheim and Novartis....
...US regulators also approved stroke-fighting drug Pradaxa for unlisted German pharmaceutical company Boehringer Ingelheim, putting it ahead in its race with rivals Bayer Healthcare and Johnson & Johnson to...
...Ingelheim, Lonza Biologics and Reckitt Benckiser....
...Abbott had sold Boehringer Ingelheim’s blockbuster arthritis drug Mobic. U.S. pharmaceutical sales fell 21.9 percent....
International Edition